CD34 and acute myeloid leukemia: This alteration significantly improved engraftment rates, requiring fewer human AML cells and for the first time, CD34+ CD38− SCID leukaemia‐initiating cells (SL‐IC) could be identified which had the potential for self‐renewal and could repopulate immune‐deficient mice and were subsequently named leukaemic stem cells.42